Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment reporting

Analytics

Phase 2
2(66.7%)
Phase 3
1(33.3%)
3Total
Phase 2(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT02918084Phase 3Active Not Recruiting

CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer

Role: lead

NCT05382741Phase 2Unknown

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

Role: lead

SYF97d8abb0dbc344d388e29a80670010a6Phase 2Unknown

Exploratory study on Azithromycin on senescence in healthy volunteers

Role: lead

All 3 trials loaded